ECE2023 Eposter Presentations Endocrine-related Cancer (80 abstracts)
1Hedi Chaker University Hospital, Department of Endocrinology, Sfax, Tunisia; 2Habib Bourguiba University Hospital, Department of Nuclear Medicine, Sfax, Tunisia.
Objective: To study the carcinological factors associated with adrenal metastases (AMT) in bronchopulmonary cancer (PBC).
Patients and Methods Casecontrol study analysing oncological data of 40 patients with PBC monitored by 18DFG PET/CT at the Nuclear Medicine Centre of Sfax, Tunisia. We compare the characteristics of 2 subgroups:
G1 (n=17): patients with PBC and META (cases)
G2 (n=23): patients with PBC without META (controls)
Results: The two groups were matched for age and gender. METAs were more common in patients with small cell carcinomas (G1: 17.6% versus G2: 0%; P=NS). A small, non-significant frequency of sarcomatoid carcinomas was observed in G1 (G1: 28.6% versus G2: 5.3%; P=NS). SUVmax (G1: 15.8±7.8 versus G2: 12.3±7) and metabolic volume (G1: 35.6±29.5 versus G2: 32.2±4.8 cm3) of PBC did not appear to influence its metastatic tropism to the adrenal glands.
According to logistic regression, the predictive factors for META were PBC size > 6 cm (OR=0.063; CI95%=[0.0120.33]; P=0.001) and the number of pre-existing secondary sites (OR=5.23; CI95%=[1.8514.78]; P=0.002).
Discussion: PBC is a neoplasm with a high metastatic potential, particularly in the adrenal glands. 18FDG PET/CT has become the gold standard for the initial assessment and monitoring of PBC. Adrenal involvement should be systematically investigated in the initial staging of PBC, particularly if it is larger than 6 cm and if another secondary location has already been established.